Granted Patent B2

US 12,331,307 · App. 17/732,141 · Granted Jun 17, 2025

Inventors: Giuseppe Pantaleo (Lausanne, CH); Thierry Calandra (Lausanne, CH); Alexandre Harari (Lausanne, CH); Thierry Roger (Lausanne, CH); Mariano Esteban (Madrid, ES); Bertram Jacobs (Phoenix, AZ); Karen Kibler (Phoenix, AZ); Cornelius Melief (Leiden, NL); Rafick-Pierre Sekaly (Montreal, CA); Elias Haddad (Montreal, CA); James Tartaglia (Toronto, CA)

Assignees: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY; CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS; IPPOX Foundation

C12N15/86A61K39/275A61K39/295A61K39/12A61K2039/5256A61K49/00C12N2710/24143

Abstract

Claims (26)

1. A recombinant NYVAC vector comprising within its genome a polynucleotide encoding:

a) C7L (SEQ ID NO: 17) and K1L (SEQ ID NO: 27), wherein the C7L (SEQ ID NO: 17) and K1L (SEQ ID NO: 27) coding sequences are adjacent to one another in the genome; or,

b) C7L (SEQ ID NO. 17) and K1L (SEQ ID NO. 27), and optionally at least one of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), and M2L (SEQ ID NO. 25); wherein the C7L (SEQ ID NO. 17) and the and K1L (SEQ ID NO. 27) are positioned adjacent to C8L and K2L, respectively, in the genome; or,

c) a polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17), a polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27), and at least one polypeptide having at least approximately 90% identity to a polypeptide selected from the group consisting of C1L (SEQ ID NO. 5), C2L (SEQ ID NO. 7), C3L (SEQ ID NO. 9), C4L (SEQ ID NO. 11), C5L (SEQ ID NO. 13), C6L (SEQ ID NO. 15), N1L (SEQ ID NO. 19), N2L (SEQ ID NO. 21), M1L (SEQ ID NO. 23), and M2L (SEQ ID NO. 25), wherein the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to C7L (SEQ ID NO. 17) is positioned adjacent to the C8L coding sequence in the genome and the at least one polynucleotide encoding the polypeptide having at least approximately 90% identity to K1L (SEQ ID NO. 27) is positioned adjacent to the K2L coding sequence in the genome; or,

d) a first polypeptide having at least about 90% identity to C7L (SEQ ID NO: 17), and a second polypeptide having at least about 90% identity to K1L (SEQ ID NO: 27), wherein polynucleotides encoding the first polypeptide and second polypeptide are positioned adjacent to one another in the genome;

wherein the recombinant NYVAC vector further comprises:

one or more modifications of at least one polynucleotide encoding B8R (SEQ ID NO. 1) that renders the vector unable to express B8R (SEQ ID NO: 1); and/or,

one or more modifications of at least one polynucleotide encoding B19R (SEQ ID NO. 3) that renders the vector unable to express B19R.

2. The recombinant NYVAC vector of claim 1 wherein the one or more modifications render the vector unable to express the at least one polypeptide.

3. The recombinant NYVAC vector of claim 1 wherein the one or more modifications render the vector unable to express B8R (SEQ ID NO. 1) or B19R (SEQ ID NO. 3).

4. The recombinant NYVAC vector of claim 1 wherein the one or more modifications render the vector unable to express B8R (SEQ ID NO. 1) and B19R (SEQ ID NO. 3).

5. The recombinant NYVAC vector of claim 1 wherein the one or more modifications comprises deletion of nucleotide sequences encoding B8R (SEQ ID NO. 2) and/or B19R (SEQ ID NO. 4).

6. The recombinant NYVAC vector of claim 1 further comprising a polynucleotide encoding ATV eIF2αH (SEQ ID NO. 29).

7. The recombinant NYVAC of claim 1 , the vector further comprising a polynucleotide encoding an immunogen.

8. The recombinant NYVAC vector of claim 7 wherein the immunogen directs an immune response against an antigen selected from the group consisting of a viral target antigen, a bacterial target antigen, a parasitic target antigen, or a tumor target antigen.

9. The recombinant NYVAC vector of claim 8 wherein the viral target antigen is derived from a virus selected from the group consisting of an adenovirus, herpes virus, epstein-barr virus, human cytomegalovirus, varicella-zoster virus, poxvirus, parvovirus, papillomavirus, reovirus, picornavirus, coxsackie virus, hepatitis A virus, poliovirus, togavirus, rubella virus, flavivirus, hepatitis C virus, yellow fever virus, dengue virus, west Nile virus, orthomyxovirus, influenza virus, rhabdovirus, paramyxovirus, measles virus, mumps virus, parainfluenza virus, respiratory syncytial virus, rhabdovirus, rabies virus, retrovirus, human immunodeficiency virus (HIV), hepadnavirus, and hepatitis B virus.

10. The recombinant NYVAC vector of claim 8 wherein the bacterial target antigen is derived from a bacterial organism selected from the group consisting of Bacillus anthracis, Bordetella pertussis, Borrelia burgdorferi, Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Campylobacter jejuni, Chlamydia pneumoniae, Chlamydia psittaci, Chlamydia trachomatis, Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, Corynebacterium diptheriae, Enterococcus faecalis, Enterococcus faecum, Escherichia coli, Francisella tularensis, Haemophilus influenza, Helicobacter pylori, Legionella pneumophila, Leptospira interrogans, Listeria monocytogenes, Mycobacterium leprae, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Neisseria gonorrhea, Neisseria meningitidis, Pseudomonas aeruginosa, Rickettsia rickettsii, Salmonella typhi, Salmonella typhinurium, Shigella sonnei, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus , coagulase negative Staphylococcus, Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyrogenes, Treponema pallidum, Vibrio cholerae , and Yersinia pestis.

11. The recombinant NYVAC vector of claim 8 wherein the parasite target antigen is derived from an organism selected from the group consisting of Ancylostoma duodenale, Anisakis spp., Ascaris lumbricoides, Balantidium coli, Cestoda spp., Cimicidae spp., Clonorchis sinensis, Dicrocoelium dendriticum, Dicrocoelium hospes, Diphyllobothrium latum, Dracunculus spp., Echinococcus granulosus, Echinococcus multilocularis, Entamoeba histolytica, Enterobius vermicularis, Fasciola hepatica, Fasciola magna, Fasciola gigantica, Fasciola jacksoni, Fasciolopsis buski, Giardia lamblia, Gnathostoma spp., Hymenolepis nana, Hymenolepis diminuta, Leishmania spp., Loa loa, Metorchis conjunctus, Metorchis albidus, Necator americanus , Oestroidea spp., Onchocercidae spp., Opisthorchis viverrini, Opisthorchis felineus, Opisthorchis guayaquilensis, Opisthorchis noverca, Plasmodium falciparum, Protofasciola robusta, Parafasciolopsis fasciomorphae, Paragonimus westermani, Schistosoma mansoni, Schistosoma japonicum, Schistosoma mekongi, Schistosoma haematobium, Spirometra erinaceieuropaei, Strongyloides stercoralis, Taenia saginata, Taenia solium, Toxocara canis, Toxocara cati, Toxoplasma gondii, Trichobilharzia regenti, Trichinella spiralis, Trichuris trichiura , Trombiculidae spp., Trypanosoma spp., Tunga penetrans , and Wuchereria bancrofti.

12. The recombinant NYVAC vector of claim 8 wherein the tumor target antigen is selected from the group consisting of a gp100 MART-1/Melan A, gp75 (TRP-1), tyrosinase, NY-ESO-1, melanoma proteoglycan a MAGE family antigen, a BAGE family antigen, a GAGE family antigen, a RAGE family antigens, N-acetylglucosaminyltransferase-V, p15, β-catenin, MUM-1, cyclin dependent kinase-4 (CDK4), p21-ras, BCR-abl, p53, p185 HER2/neu, epidermal growth factor receptor (EGFR), carcinoembryonic antigen (CEA), a carcinoma-associated mutated mucin, MUC-1, prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), KSA, kinesin 2, HIP-55, TGFβ-1 anti-apoptotic factor, tumor protein D52, H1FT, NY-BR-1, NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-87, NY-BR-96, and a pancreatic cancer antigen.

13. A composition comprising a recombinant NYVAC vector of claim 1 and a pharmaceutically acceptable carrier.

14. A method of immunizing a host against a viral target antigen, a bacterial target antigen, a parasitic target antigen, or a tumor target antigen comprising administering to the host a composition of claim 13 to the host.

15. The method of claim 14 wherein administration of the composition affects cells of the host immune system as determined by detecting a change in at least one immune cells characteristic selected from the group consisting of maturation, proliferation, improved direct presentation of antigen, improved cross-presentation of antigen, and an activated immunodulatory gene expression profile.

16. The method of claim 15 wherein the immune cells comprise one or more cell types selected from the group consisting of dendritic cells, lymphocytes, monocytes, macrophages, natural killer cells, and granulocytes.

17. The method of claim 16 wherein the lymphocytes are cytotoxic T cells.

18. The method of claim 16 wherein the lymphocytes are B cells.

19. The method of claim 14 wherein the method induces a protective immune response.

Assignments (10)

Continuity (5)

References Cited (164)